Roehm Gmbh Chemische Fabrik

Evonik Roehm Gmbh

Rohm Gmbh

Roehm Gmbh & Co Kg

Glaxo Group Limited

Evonik Rohm Gmbh

Hans-ulrich Petereit

Manfred Assmus

Hans-Ulrich Petereit

Thomas Beckert

Klaus Lehmann

Guenter Bergmann

Stephanie Kaehler

Werner Hoess

Christian Meier

Thomas Riermeier

Hartmut Schikowsky

Jan Hendrik Schattka

Florian Hermes

Kathrin Nollenberger

Thomas Dassinger

Wolfgang Fuchs

Werner Hoss

Rene Leubert

René Leubert

The invention relates to a coating composition suitable for the coating of a pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process, wherein either the core of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer or vice versa.

Coating composition suitable for pharmaceutical or nutraceutical dosage forms

The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of Cto Calkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group, at least 4 percent of which are neutralized by means of a base, for producing a medicament that is provided with an active substance-containing core and is coated with the partially neutralized, anionic (meth)acrylate copolymer. The medicament releases at least 30 percent of the active substance contained therein in 30 minutes at a pH at which the active substance is sufficiently soluble and stable and at which the corresponding medicament that is coated with the non-neutralized anionic (meth)acrylate polymer releases less than 10 percent of the active substance contained therein.

Use of a partially neutralized, anionic (meth) acrylate copolymer as a coating for the production of a medicament pharmaceutical form releasing active substance at reduced pH values

The invention relates to a process for making molded articles by means of injection molding with the process steps of a) melting of a (meth)acrylate copolymer, which is composed of 30 to 80 wt % of radical-polymerized C1 to C4 alkyl esters of acrylic or methacrylic acid and 70 to 20 wt % of (meth)acrylate monomers with a tertiary ammonium group in the alkyl residue, wherein the (meth)acrylate copolymer is present in a mixture with 1 to 70 wt % of a plasticizer and a desiccant in the ratio of 1:1 to 1:20 and also with 0.05 to 5 wt % of a release agent, and further standard additives or adjuvants and if necessary even a pharmaceutical active principle can also be present in the mixture, and before the mixture is melted it has a content of more than 0.5 wt % of low-boiling constituents with a vapor pressure of at least 1.9 bar at 120&deg; C., b) degassing of the mixture in the thermoplastic condition at temperatures of at least 120&deg; C., whereby the content of low-boiling constituents with a vapor pressure of at least 1.9 bar at 120&deg; C. is lowered to at most 0.5 wt % and c) injection of the melted and degassed mixture into the mold cavity of an injection-molding die, wherein the mold cavity has a temperature which lies at least 10&deg; C. below the glass transition temperature of the (meth)acrylate copolymer, cooling of the melt mixture and removal of the obtained molded article from the mold.

Injection molding method for (meth)acrylate copolymers having tertiary ammonium groups

An adhesive binder for dermal or transdermal therapy systems consists of the following components:

Adhesive binders for dermal or transdermal therapy systems

The invention relates to an adhesive and binder for dermal or transdermal therapy systems, that includes (a) 85-99.9 weight % of (meth)acrylate copolymer of structural and functional monomers, where the functional monomers have tertiary or quaternary amino groups, (b) 0.1-15 weight % of an organic dicarboxylic or tricarboxylic acid, and (c) 40-70 weight %, relative to the total of (a) and (b), of a plasticizer.

Hydrophilic adhesive and binder for medications

A dermal therapeutic system which exhibits a prolonged release of a drug comprising at least one pharmaceutical agent combined with poly(meth)acrylates in the form of at least one layer of the therapeutic system, the poly(meth)acrylates being a mixture, which is produced from a melt, comprising (1) at least one (meth)acrylic polymer containing functional groups and (2) at least one (meth)acrylic polymer which regulates the flow behavior of the poly(meth)acrylate mixture and which contains no functional groups or only insignificant amounts of functional groups.

Dermal therapeutic system made of a meltable poly (meth) acrylate

Ranitidine salts with polycarboxylic acids, such as copolymers of acrylic and/or methacrylic acid with their lower alkyl esters, are water-soluble salts with a very reduced bitter taste. The salts are suitable as liquid gastritis preparations.

Debittered ranitidine preparation

A water insoluble lipophilic emulsifier having a hydrophile-lipophile balance (HLB) of 3.5 to 7, added to an aqueous dispersion containing a polymer comprising acrylic acid, methacrylic acid, their alkyl esters, and/or their alkylaminoalkyl esters, acts as a lubricant and parting agent when the resulting mixture is used for coating pharmaceutical dosage forms and prevents the pharmaceutical dosage forms being coated from sticking to one another and to the walls of the coating apparatus used.

Aqueous film coating agent for solid medicaments

Growing community of inventors

Bickenbach, Germany

Manfred Assmus